CA2224738C - Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids - Google Patents

Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids Download PDF

Info

Publication number
CA2224738C
CA2224738C CA002224738A CA2224738A CA2224738C CA 2224738 C CA2224738 C CA 2224738C CA 002224738 A CA002224738 A CA 002224738A CA 2224738 A CA2224738 A CA 2224738A CA 2224738 C CA2224738 C CA 2224738C
Authority
CA
Canada
Prior art keywords
cytochrome
monooxygenase
pharmaceutically acceptable
metabolized
ritonavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002224738A
Other languages
French (fr)
Other versions
CA2224738A1 (en
Inventor
Daniel W. Norbeck
Dale J. Kempf
John M. Leonard
Richard J. Bertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26667933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2224738(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2224738A1 publication Critical patent/CA2224738A1/en
Application granted granted Critical
Publication of CA2224738C publication Critical patent/CA2224738C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.

Description

USE OF RITONAVIR (ABT-538) FOR IMPROVING THE
PHARMACOKINETICS OF DRUGS METABOLIZED BY CYTOCHROME

Technical Field The present invention relates to a novel composition and a method for improving the pharmacokinetics of drugs which are metabolized by cytochrome P450 monooxygenase. In addition, the present invention relates to a novel composition and a method for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease and a composition and a method for inhibiting a retroviral infection, in particular an HIV
infection.
Background of the Invention Infection by the retrovirus known as human immumodeficiency virus (HIV) continues to be a serious human health problem. Methods for treating HIV
infections include administering agents which inhibit the activity of viral enzymes which are essential to the life cycle of the virus.
The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the Col and g-ag gene products. See Wellink, Arch. Virol. 98 1 (1988). Retroviral proteases most commonly process the ~g precursor into core proteins, and also process the Col precursor into reverse transcriptase and retroviral protease. Retroviral proteases are known to be sequence specific. See Pearl, Nature ~2$ 482 (1987).
The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford, J.
Virol.
~3_ 899 (1985); Katoh, et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy. See Mitsuya, Nature ~ 775 (1987).
It has recently been disclosed that the HIV protease inhibitor ritonavir (also known as ABT-538) is effective in humans for inhibiting an HIV
infection.
It has also been discovered that ritonavir is an inhibitor of the metabolic enzyme cytochrome P450 monooxygenase.
Some drugs and, in particular, some HIV protease inhibitors are metabolized by cytochrome P450 monooxygenase, leading to unfavorable pharmacokinetics and the need for more frequent and higher doses than are most desirable. Administration of such drugs with an agent that inhibits metabolism by cytochrome P450 monooxygenase will improve the pharmacokinetics (i.e., increase half-life, increase the time to peak plasma concentration, increase blood levels) of the drug.
It has been discovered that coadministration of ritonavir with a drug which is metabolized by cytochrome P450 monooxygenase, especially the P450 3A4 isozyme, causes an improvement in the pharmacokinetics of such a drug.
In particular, it has been discovered that coadministration of ritonavir with an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase causes an unexpected improvement in the pharmacokinetics of such an HIV protease inhibitor.
Disclosure of the Invention In accordance with the present invention, there is disclosed a method of improving the pharmacokinetics of a drug (or a pharmaceutically acceptable salt thereof) which is metabolized by cytochrome P450 monooxygenase s comprising coadministering ritonavir or a pharmaceutically acceptable salt thereof. When administered in combination, the two therapeutic agents can bo formulated as separate compositions which are administered at the same time or different times, or the two therapeutic agents can be administered as a single composition.
Drugs which are metabolized by cytochrome P450 monooxygenase and which benefit from coadministration with ritonavir include the immunosuppressants cyclosporine, FK-506 and rapamycin, the chemotherapeutic agents taxol and taxotere, the antibiotic clarithromycin aid the H1V protease inhibitors A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629 (N,N-dimethylglycyl-N-(2-hyrdoxy-3-(((4-methoxyphenyl)sulphonyl)(2-methylpropyl)amino}-1-(phenyfmethyl)propyl)-3-methyl-L-valinamide), KNI-272, CGP 53437, CGP 57813 and U-103017.
In a preferred embodiment of the present invention, there is disclosed a method for improving the pharmacokinetics of an HIV protease inhibitor (or a pharmaceutically acceptable salt thereof) which is metabolized by cytochrome P450 monooxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt thereof. Such a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor or a pharmaceutically acceptable salt thereof which is metabolized by cytochrome P450 monooxygenase is useful for inhibiting H1V protease in humans and is also useful for inhibition, treatment or prophylaxis of an HIV infection or AIDS
(acquired immune deficiency syndrome) in humans. When administered in combination, the two therapeutic agents can be formulated as separate compositions which are administered at the same time or different times, or the two therapeutic agents can be administered as a single composition.

-3a-In another aspect of the invention there is provided use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase.
In still another aspect of the invention there is provided use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase.
In yet another aspect of the invention there is provided ritonavir or a pharmaceutically acceptable salt thereof for use in improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
In a still further aspect of the invention there is provided use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting cytochrome P450 monooxygenase.
In yet a further aspect of the invention there is provided a cytochrome P450 monooxygenase inhibitor pharmaceutical composition comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
In a further aspect of the invention there is provided a pharmaceutical composition for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

-3b-In yet another aspect of the invention there is provided a pharmaceutical composition for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
In still another aspect of the invention there is provided a pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier, ritonavir or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor and a therapeutically effective amount of a HIV
protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.
In still another aspect of the invention there is provided a pharmaceutical composition for inhibiting an HIV infection comprising a pharmaceutical carrier, ritonavir or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor and a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention there is provided a pharmaceutical combination for inhibiting HIV protease comprising a first pharmaceutical dosage which comprises ritonavir, or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor, in association with a first pharmaceutically acceptable carrier; and a second pharmaceutical dosage which comprises a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof, in association with a second pharmaceutically acceptable carrier.

-3c-In still another aspect of the invention there is provided a pharmaceutical combination for inhibiting a HIV infection comprising a first pharmaceutical dosage which comprises ritonavir, or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor, in association with a first pharmaceutically acceptable carrier; and a second pharmaceutical dosage which comprises a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof, in association with a second .
pharmaceutically acceptable carrier.
Preferred HIV protease inhibitors which are metabolized by cytochrome P450 monooxygenase include A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

Ritonavir is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)-methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof. Ritonavir can be synthesized by the procedures disclosed in PCT
Patent Application No. W094/14436, published July 7, 1994, and the U.S. patent 5,567,823.
VX-478 is O NON
~S~
O i O O
O Ph or a pharmaceutically accepi:able salt thereof. VX-478 can by synthesized by the procedures disclosed in PCT' Patent Application No. W094/05639, published March 17, 1994.
A-77003 is (2S,3R,4S,5S)-2,5-Di-(N-((N-methyl)-N-((2-pyridinyl)methyl)-amino)carbonylvalinylamino)-3,4-dihydroxy-1,6-diphenyl hexane or a pharma-ceutically acceptable salt thereof and is disclosed in U.S. Patent No.
5,142,056, issued August 25, 1992.
A-80987 is (2S,3S,5S)-2-(N-(N-((2-Pyridinyl)methoxycarbonyl)valinyl)-amino)-5-(N-(3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and is disclosed in U.S. Patent No.
5,354,866, issued October 11, 1994.
MK-639 is N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-)-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP541168, published May 12, 1993 and U.S.

Patent No. 5,413,999, issued May 9, 1995.
Saquinavir is N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide or a pharmaceutically acceptable salt thereof and is disclosed in U.S. Patent No. 5,196,438, issued March 23, 1993.
AG 1343 is H,,,, OH
I = ~'' H
H O ~' H w/'~ N
O
PhS O H
or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. W095/0984:3, published April 13, 1995 and U.S. Patent No.
5,484,926, issued January 16, 1996.
DMP-323 is O -HO N N ~ ~ OH
HO OH ~
pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. W093/07128, published April 15, 1993.

XM-a5o is o _ N"N

HO OH ~
or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. W093/07128, published April 15, 1993.
BILA 2011 BS is N
\ \ OH O
N~ Val-NH~N
O
\ O H
or a pharmaceutically accept~ible salt thereof and is disclosed in European Patent Application No. EP560268, published September 15, 1993.
BILA 1096 BS is N
\ \ OH S
Val-N H~:~ N
C) y ~ H
or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP560268, published September 15, 1993.

BILA 2185 BS is ~ ~N
\ I
\ \ OH S
N ~~Val-NH~N
\
I ~ H
or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP560268, published September 15, 1993.
BMS 186,318 is OH H OH
BocNH~N NHBoc Phi I \
O NJ
O
or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP580402, published January 26, 1994.
LB71262 is O

O °=
CH3 H3C' H3C S02CH;
and is disclosed in European Patent Application No. EP687675, published December 20, 1995.

_g_ SC-52151 is [1S-[1R*(R*),2S*];I-N1 [3-[[[(l,l-dimethylethyl)amino]carbonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl) propyl]-2- [(2-quinolinyl-carbonyl)amino]-butanediamide or a pharmaceutically acceptable salt thereof and is disclosed in PC'T Patent Application No. W092/08701, published May 29, 1992 and PCT Patent Application No. W093/23368, published November 25, 1993.
SC-629 (N,N-dimethylgl5~cyl-N-(2-hyrdoxy-3-(((4 methoxyphenyl)-suiphonyl) (2-methylpropyl)amino)-1 -(phenylmethyl)propyl)-3-methyl-L-valinamide) is i H3 O t-Bu OH CH3 H
H3C'~N~ N N~
SOZ ~ ~ OCH3 O

or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. W095/06030, published March 2, 1995.
KNI-272 is O SCH 3 OH rS
O~. N N N
Fi o i o Ph O
H
or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP574135, published December 15, 1993.

CGP 53437 is Ph OH
BocNH Val-Phe- N O
Phi O
and is disclosed in European Patent Application No. EP532466, published March 17, 1993.
OGP 57813 is nH
BocNH Vai-Phe-N O
U
Phi O
and is disclosed in European Patent Application No. EP618222, published October 5, 1994.
U-103017 is OH
I a~ I w 0 0 ~ , cN
HN.S
,, ,, O O
and is disclosed in PCT Patent Application No. W094/418188, published August 18, 1994.

The terms "S" and "R" configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl.
Chem. (1976) 45, 13 - 30.
The term "Val" as used herein refers to valine. Unless otherwise noted, when "Val" is used herein it refers to the L-isomer. In general, the amino acid abbreviations used herein follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature for amino acids and peptides (Eur. J. Biochem.
1984, 1~5$, 9-31 ).
The ability of a compound to inhibit HIV protease can be demonstrated according to the methods disclosed in PCT Patent Application No.
W094/14436.
The ability of an HIV protease inhibitor to inhibit an HIV infection can be demonstrated according to the methods disclosed in PCT Patent Application No. W094/14436.
Inhibition of C,~rtochrome P450 The ability of ritonavir to inhibit cytochrome P450 monooxygenase activity was tested with terfenadine as the probe substrate (Yun, et al., Drug Metabolism & Disposition, Vol. 21 403-407 (1993)). Ritonavir inhibited the terfenadine hydroxylase activity representing the most abundant form of cytochrome P450 (CYP3A4) present in human liver with an IC5o of 0.25 ~M.
Pharmacokinetic Improvement The ability of ritonavir to improve the pharmacokinetics of a compound which is metabolized by cytochrome P450 monooxygenase can be demonstrated by the test method described below, wherein VX-478 is used as an example.
Rats (male, Sprague-Dawley derived, 0.3-0.45 kg) were fasted overnight prior to dosing, but were permitted water ad libitum. For combination dosing, a single solution containing both ritonavir and VX-478 (5 mg/ml each) was prepared in a vehicle of 20% ethanol : 30% propylene glycol and D5W with an appropriate number of molar equivalents of methane sulfonic acid to assist in solubilization. Separate solutions of VX-478 and ritonavir were also prepared and these solutions were used to evaluate the pharmacokinetics of VX-478 and ritonavir when administered as a single agent in rats. The solutions, administered orally by gavage to a group of rats at a dose volume of 2 mUkg, provided a 10 mg/kg dose of each compound. Blood samples were obtained from a tail vein of each rat 0.25, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours after dosing.
The plasma was separated from the red cells by centrifugation and frozen (-30°C) until analysis. Concentrations of both ritonavir and VX-478 were determined simultaneously by reverse phase HPLC with low wavelength UV
detection following liquid-liquid extraction of the plasma samples. The peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax) for each rat were obtained directly from the plasma concentration data. The area under the curve was calculated by the trapezoidal method over the time course of the study. The plasma elimination half life was obtained from NONLIN84 or from a log-linear regression of the terminal plasma concentrations as a function of time after dosing. Each combination was evaluated in a group containing at least three rats; the values reported are averages for each group of animals. The data obtained from the combination was compared to data obtained from a separate group of rats which received a single, separate dose of the compound under evaluation.
Below in Table 1 are shown the results from the pharmacokinetic experiments with VX-478 and other HIV protease inhibitors in rats. The maximum plasma levels (Cn-,ax), time to maximum plasma level (Tmax) and area under the plasma concentration curve (AUC) for an 8-hour sampling interval following dosing of the HIV protease inhibitor alone vs. dosing in com-bination with ritonavir are provided.

Table 1 Cmax Tmax AUC(0-8h) Compound me /ml hr (mc hr/ml) VX-478$ 1.61 0.42 1.69 VX-478 (+ritonavir)2.88 1.5 13.50 A-77003$ 0.07 0.25 0.025 A-77003 (+ritonavir)0.96 0.67 1.39 A-80987$ 2.42 0.25 1.45 A-80987 (+ritonavir)4.47 1.7 25.74 Saquinavir$ 0.08 0.18 0.029 Saquinavir {+ritonavir)1.48 3.0 8.52 MK-639$ 1.03 0.5 0.81 MK-639 (+ritonavir)1.40 3.0 6.51 AG 1343$ 0.40 0.75 1.14 AG1343 (+ritonavir)1.81 4.0 11.92 $ compound administered as a single agent The ability of ritonavir to improve the pharmacokinetics of clarithromycin in humans was demonstrated according to the method described below.
Clarithromycin {500 mg/BIAXIN~ tablet every 12 hours) and a combination of ritonavir {200 mg of liquid formulation every 8 hours) and clarithromycin {500 mg every 12 hours) were administered to groups of 4 healthy human volunteers. Blood samples were collected on day four of dosing for HPLC determination of plasma concentrations of clarithromycin.
Below in Table 2 are shown the results from the pharmacokinetic experiments with clarithromycin in humans. The mean maximum plasma levels (Cmax) and area under the plasma concentration curve (AUC) calculated using noncompartmental methods for the 0-24 hour time interval on day four of dosing of clarithromycin alone vs. dosing in combination with ritonavir are provided.

Table 2 Cmax AUC(0-24h) Com op and m ml lmca~hr/ml~
clarithromycin$ 3.93 49.04 clarithromycin (+ritonavir) 5.13 86.88 $ compound administered as a single agent The therapeutic agents of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides;
dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, malefic acid, succinic acid and citric acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

The administration of ritonavir and a compound which is metabolized by cytochrome P450 monooxygenase is useful for improving in humans the pharmacokinetics of the compound which is metabolized by cytochrome P450 monooxygenase.
In particular, the administration of ritonavir and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase is useful for improving in humans the pharmacokinetics of the HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase.
The combination of ritonavir and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase is also useful for inhibiting a retroviral protease, in particular HIV protease, in vitro or inin vivo (especially in mammals and in particular in humans). This combination of therapeutic agents is also useful for the inhibition of retroviruses in vivo, especially human immunodeficiency virus (HIV). This combination of therapeutic agents is also useful for the treatment or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection, in a human or other mammal.
The total daily dose of ritonavir to be administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.001 to 300 mg/kg body weight daily and more usually 0.1 to 50 mg/kg and even more usually 0.1 to 25 mg/kg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
The total daily dose of the drug which is metabolized by cytochrome P450 monooxygenase to be administered to a human or other mammal is well known and can be readily determined by one of ordinary skill in the art.
Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form of each drug, individually or in combination, will vary depending upon the host treated and the particular mode of administration.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
The combination of therapeutic agents of the present invention (as individual compositions or as a single composition) may be administered orally, parenterally, sublingually, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
The combination of therapeutic agents of the present invention (as individual compositions or as a single composition) can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or mufti-lamellar hydrated liquid crystals that are dispersed in an aqueous medium.
Any non-toxic, physiologically aceptable arid metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic.
Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.
Preferred dosage forms for ritonavir include (a) a liquid dosage form for oral administration as disclosed in U.S. Serial No. 08/283, 239, filed July 29, 1994 (now U.S.
Patent No. 5,484,801, issued January 16, 1996); (b) an encapsulated solid or semi-solid dosage form as disclosed in PC'C Patent Application No. W095/07696, published March 23, 1995 and U.S. Patent 5,948,436, and (c) an encapsulated solid dosage form as disclosed in PC'T Patent Application No. W095/09614, published April 13, 1995.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

Claims (66)

1. Use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase.
2. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA
2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
3. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is an HIV protease inhibitor.
4. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG 1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
5. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.
6. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.
7. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.
8. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.
9. The use of claim 1, wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.
10. The use of any one of claims 1 to 9, wherein the cytochrome P450 monooxygenase is P450 3A4.
11. Use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase.
12. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is an HIV protease inhibitor.
13. The use of claim 11, wherein the drug which is metabolized to cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA
2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
14. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG 1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
15. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.
16. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.
17. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.
18. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.
19. The use of claim 11, wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.
20. The use of any one of claims 11 to 19, wherein the cytochrome P450 monooxygenase is P450 3A4.
21. Ritonavir or a pharmaceutically acceptable salt thereof for use in improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
22. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA
1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
23. The use of claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is an HIV protease inhibitor.
24. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG 1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CCP 53437, CGP 57813 and U-103017.
25. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.
26. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.
27. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.
28. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.
29. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 21, wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.
30. Ritonavir or a pharmaceutically acceptable salt thereof according to any one of claims 21 to 29, wherein the cytochrome P450 monooxygenase is P450 3A4.
31. Ritonavir or a pharmaceutically acceptable salt thereof for use in increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase.
32. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA
1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
33. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is an HIV protease inhibitor.
34. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG 1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
35. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.
36. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.
37. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.
38. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.
39. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 31, wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG 1343.
40. Ritonavir or a pharmaceutically acceptable salt thereof according to any one of claims 31 to 39, wherein the cytochrome P450 monooxygenase is P450 3A4.
41. Use of ritonavir or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting cytochrome P450 monooxygenase.
42. Use according to claim 41, wherein the cytochrome P450 monooxygenase is P450 3A4.
43. Ritonavir or a pharmaceutically acceptable salt thereof for use in inhibiting cytochrome P450 monooxygenase.
44. Ritonavir or a pharmaceutically acceptable salt thereof according to claim 43, wherein the cytochrome P450 monooxygenase is P450 3A4.
45. A cytochrome P450 monooxygenase inhibitor pharmaceutical composition comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
46. A pharmaceutical composition for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
47. A pharmaceutical composition for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising an acceptable, cytochrome P450 monooxygenase inhibiting amount of ritonavir or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
48. A pharmaceutical composition according to claim 45, 46 or 47, wherein said inhibiting amount inhibits the cytochrome P450 monooxygenase P450 3A4.
49. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier, ritonavir or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor and a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.
50. A pharmaceutical composition for inhibiting an HIV infection comprising a pharmaceutical carrier, ritonavir or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor and a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof.
51. A pharmaceutical composition according to claim 49 or 50, wherein said HIV protease inhibitor is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017, or a pharmaceutically acceptable salt thereof.
52. A pharmaceutical composition of claim 51, wherein the HIV
protease inhibitor is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG 1343.
53. A pharmaceutical composition of claim 51, wherein the HIV
protease inhibitor is saquinavir.
54. A pharmaceutical composition of claim 51, wherein the HIV
protease inhibitor is VX-478.
55. A pharmaceutical composition of claim 51, wherein the HIV
protease inhibitor is MK-639.
56. A pharmaceutical composition of claim 51, wherein the HIV
protease inhibitor is AG 1343.
57. A pharmaceutical composition according to any one of claims 49 to 56; wherein said monooxygenase inhibitor inhibits the cytochrome P450 monooxygenase P450 3A4.
58. A pharmaceutical combination for inhibiting HIV protease comprising a first pharmaceutical dosage which comprises ritonavir, or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor, in association with a first pharmaceutically acceptable carrier; and a second pharmaceutical dosage which comprises a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof, in association with a second pharmaceutically acceptable carrier.
59. A pharmaceutical combination for inhibiting a HIV infection comprising a first pharmaceutical dosage which comprises ritonavir, or a pharmaceutically acceptable salt thereof, for use as a cytochrome P450 monooxygenase inhibitor, in association with a first pharmaceutically acceptable carrier; and a second pharmaceutical dosage which comprises a therapeutically effective amount of a HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase or a pharmaceutically acceptable salt thereof, in association with a second pharmaceutically acceptable carrier.
60. A pharmaceutical combination according to claim 58 or 59, wherein said HIV protease inhibitor is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG 1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.
61. A pharmaceutical combination according to claim 58 or 59, wherein said HIV protease inhibitor is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.
62. A pharmaceutical combination according to claim 58, or 59, wherein said HIV protease inhibitor is saquinavir.
63. A pharmaceutical combination according to claim 58 or 59, wherein said HIV protease inhibitor is VX-478.
64. A pharmaceutical combination according to claim 58 or 59, wherein said HIV protease inhibitor is MK-639
65. A pharmaceutical combination according to claim 58 or 59, wherein said HIV protease inhibitor is AG 1343.
66. A pharmaceutical combination according to any one of claims 58 to 65, wherein said monooxygenase inhibitor inhibits the cytochrome P450 monooxygenase P450 3A4.
CA002224738A 1995-06-29 1996-06-28 Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids Expired - Lifetime CA2224738C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65495P 1995-06-29 1995-06-29
US60/000,654 1995-06-29
US384995P 1995-09-15 1995-09-15
US60/003,849 1995-09-15
PCT/US1996/011015 WO1997001349A1 (en) 1995-06-29 1996-06-28 Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids

Publications (2)

Publication Number Publication Date
CA2224738A1 CA2224738A1 (en) 1997-01-16
CA2224738C true CA2224738C (en) 2002-08-27

Family

ID=26667933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224738A Expired - Lifetime CA2224738C (en) 1995-06-29 1996-06-28 Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids

Country Status (14)

Country Link
US (2) US6037157A (en)
EP (7) EP0871465B1 (en)
JP (4) JP4023823B2 (en)
KR (2) KR20070120619A (en)
AT (2) ATE225186T1 (en)
AU (1) AU722812B2 (en)
CA (1) CA2224738C (en)
DE (3) DE69624136T2 (en)
DK (4) DK0871465T3 (en)
ES (4) ES2304416T3 (en)
HK (4) HK1016088A1 (en)
IL (1) IL122546A (en)
PT (4) PT871465E (en)
WO (1) WO1997001349A1 (en)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843946A (en) 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
UA49803C2 (en) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA979327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
KR19990016002A (en) * 1997-08-12 1999-03-05 성재갑 Chitochrome P450 substrate containing L7171350
KR19990016003A (en) * 1997-08-12 1999-03-05 성재갑 Chitochrome Inhibitor Composition
KR100348561B1 (en) * 1997-08-12 2002-09-18 주식회사 엘지씨아이 Composition containing lb71350 and dmp450
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
CA2336160C (en) 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of compounds for treating hiv
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
CA2346131C (en) * 1998-11-04 2013-01-15 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
EP1712231A3 (en) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Method for improving the pharmacokinetics of tipranavir
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DK1183026T3 (en) * 1999-06-04 2006-11-06 Abbott Lab Improved pharmaceutical formulations comprising ritonavir
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
ES2304990T3 (en) 2000-01-19 2008-11-01 Abbott Laboratories PHARMACEUTICAL FORMULATIONS OF IMPROVED HIV PROTEASA INHIBITORS.
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
AR037797A1 (en) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd COMBINATION OF PROTEASA INHIBITORS DEPENDENTS OF CITOCROMO P450
JP4625637B2 (en) 2002-02-22 2011-02-02 シャイア エルエルシー Active substance delivery system and method for protecting and administering an active substance
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
WO2004054586A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim International Gmbh Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US7320961B2 (en) 2003-03-24 2008-01-22 Abbott Laboratories Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
TW200518669A (en) * 2003-09-12 2005-06-16 Vertex Pharma Animal model for protease activity and liver damage
AU2004282148A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004285019B9 (en) * 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
RU2006127429A (en) * 2004-01-30 2008-02-10 Пфайзер Инк. (US) COMPOSITIONS INCLUDING AN HIV-PROTEASE INHIBITOR AND ENZYMATIVE ACTIVITY INHIBITOR OF CYTOCHROME P450
CA2554999A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
AU2005291918A1 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease inhibition
TW201424733A (en) 2004-10-29 2014-07-01 Vertex Pharma Dose forms
EP1814548A1 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
CA2585663A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
AR053845A1 (en) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-TIAZOLILMETIL [(1S, 2R) -3 - [[(2-AMINO-6-BENZOXAZOLIL) SULFONIL)] (2-METHYLPROPIL) AMINO] -2-HYDROXY-1- (PHENYLMETIL) PROPIL] CARBAMATE AS A PHARMACY IMPROVER METABOLIZED BY THE CYCROCHROME P450
CA2606025A1 (en) * 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
WO2007014924A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
MY139988A (en) * 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PL1912997T3 (en) * 2005-07-29 2012-02-29 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
EP1919899B1 (en) * 2005-07-29 2011-01-19 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
PE20070210A1 (en) 2005-07-29 2007-04-16 Tibotec Pharm Ltd MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
CN101273027B (en) * 2005-07-29 2015-12-02 爱尔兰詹森科学公司 The macrocyclic hcv inhibitors of hepatitis C virus
TWI383980B (en) * 2005-07-29 2013-02-01 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
ES2401661T3 (en) * 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Serine protease inhibitors
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2632095A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
EP1971611B1 (en) * 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
ES2378473T3 (en) * 2005-12-21 2012-04-12 Abbott Laboratories Antiviral compounds
US7763731B2 (en) * 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
MX2008011429A (en) * 2006-03-06 2008-09-18 Abbott Lab Compositions and methods of use of ritonavir for treating hcv.
KR20080112303A (en) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 Deuterated hepatitis c protease inhibitors
CA2647158C (en) * 2006-03-23 2012-07-31 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
BRPI0710878A2 (en) 2006-04-11 2015-03-31 Novartis Ag Organic compounds and their uses
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
NO347119B1 (en) * 2006-07-07 2023-05-15 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
NZ573060A (en) 2006-07-07 2012-02-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2661873A1 (en) 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
AU2007337830A1 (en) * 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors
US20080181948A1 (en) 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
JP2010510192A (en) 2006-11-17 2010-04-02 テイボテク・フアーマシユーチカルズ・リミテツド Macrocyclic inhibitor of hepatitis C virus
CN105254637A (en) * 2007-02-08 2016-01-20 爱尔兰詹森科学公司 Pyrimidine substituted macrocyclic inhibitors
RS55195B1 (en) * 2007-02-23 2017-01-31 Gilead Sciences Modulators of pharmacokinetic properties of therapeutics
LT2487166T (en) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
KR20090115970A (en) * 2007-02-27 2009-11-10 버텍스 파마슈티칼스 인코포레이티드 Co-crystals and pharmaceutical compositions comprising the same
CA2679426A1 (en) * 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
DE602008005462D1 (en) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co TABLETTED ATAZANA-CONTAINING COMPOSITIONS
MX2009013504A (en) * 2007-06-22 2010-03-26 Bristol Myers Squibb Co Tableted compositions containing atazanavir.
AU2008268537B2 (en) * 2007-06-22 2012-11-01 Bristol-Myers Squibb Holdings Ireland Tableted compositions containing atazanavir
ES2360336T3 (en) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company COMPOSITIONS IN TABLETS CONTAINING ATAZANAVIR.
AU2008275744A1 (en) * 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
JP5443360B2 (en) * 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal and pharmaceutical composition containing the same
CA2703918C (en) * 2007-10-29 2016-10-18 Cipla Limited Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
UA103013C2 (en) * 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Amide compounds as boosters of antivirals
PA8809601A1 (en) * 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
CA2710679A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
CN101959506A (en) * 2008-02-28 2011-01-26 雅培制药有限公司 Tablets and preparation thereof
US20090318561A1 (en) * 2008-06-23 2009-12-24 Mutual Pharmaceutical Company, Inc. Colchicine products, method of manufacture, and methods of use
TW201012814A (en) 2008-07-01 2010-04-01 Centocor Ortho Biotech Products L P Cyclopropyl polymerase inhibitors
TWI454476B (en) 2008-07-08 2014-10-01 Tibotec Pharm Ltd Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
NZ591951A (en) * 2008-10-07 2013-02-22 Janssen R & D Ireland New amide compounds as boosters of antivirals
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
CN102245604A (en) 2008-12-23 2011-11-16 雅培制药有限公司 Anti-viral compounds
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073632B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
WO2010077061A2 (en) * 2008-12-31 2010-07-08 한올바이오파마 주식회사 Pharmaceutical formulations containing antiviral drugs
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US20100261731A1 (en) * 2009-04-13 2010-10-14 Abbott Laboratories Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
AU2010240893B2 (en) * 2009-04-25 2015-02-05 F. Hoffmann-La Roche Ag Methods for improving pharmacokinetics
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ591973A (en) * 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110046227A1 (en) * 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
WO2011092687A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Hk Limited Process for the preparation of darunavir and darunavir intermediates
RU2012136824A (en) 2010-01-29 2014-03-10 Вертекс Фармасьютикалз Инкорпорейтед METHODS FOR TREATING HEPATITIS C VIRAL INFECTION
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2598159A4 (en) * 2010-07-30 2014-01-08 Merck Sharp & Dohme Inhibition of cyp3a drug metabolism
BR112013008510A2 (en) 2010-10-08 2016-07-05 Novartis Ag vitamin e ns3 sulfamide inhibitor formulations
MX2013006951A (en) 2010-12-16 2013-10-03 Abbvie Inc Anti-viral compounds.
EP2651924A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
US20140288108A1 (en) 2011-11-28 2014-09-25 Ranbaxy Laboratories Limited Process for the preparation of solid dispersion of lopinavir and ritonavir
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CN104780921A (en) * 2012-08-31 2015-07-15 杨森制药公司 Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside hcv inhibitor and ritonavir
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
UA117375C2 (en) 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
US20160271160A1 (en) 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
IN2014CH00872A (en) 2014-02-21 2015-08-28 Mylan Lab Ltd
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2844848T3 (en) 2015-04-21 2021-07-22 Eiger Biopharmaceuticals Inc Pharmaceutical compositions comprising Lonafarnib and Ritonavir
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US384995A (en) 1888-06-26 moore
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0558603B1 (en) 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
KR100268694B1 (en) 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 Cyclic ureas and analogues useful as retroviral protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
SG52731A1 (en) 1991-11-08 1998-09-28 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids
DE69300043T2 (en) 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituted pipecoline acid derivatives as HIV protease inhibitors.
EP0574135B1 (en) 1992-05-13 1998-11-18 Japan Energy Corporation Process for producing peptide derivatives and salts thereof
ATE141265T1 (en) 1992-05-20 1996-08-15 Searle & Co METHOD FOR PRODUCING INTERMEDIATES IN THE SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
PT727419E (en) * 1992-12-29 2002-08-30 Abbott Lab INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF RETROVIRAL PROTEASE INHIBITORS
IL108459A0 (en) 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
EP0618222A3 (en) 1993-03-11 1997-01-02 Ciba Geigy Ag Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid.
AU676299B2 (en) * 1993-06-28 1997-03-06 Akira Fujishima Photocatalyst composite and process for producing the same
ATE174587T1 (en) 1993-08-24 1999-01-15 Searle & Co HYDROXYAMINOSULFONAMIDES USABLE AS INHIBITORS OF RETROVIRAL PROTEASES
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
WO1995010281A1 (en) 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
WO1995011992A1 (en) * 1993-10-27 1995-05-04 The Regents Of The University Of California Antiviral compounds
KR0125117B1 (en) 1994-06-15 1997-12-05 성재갑 Novel hiv protease inhibitors with anti aids effect and the process for preparation thereof
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
UA49803C2 (en) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
IL114808A (en) * 1994-08-11 1999-10-28 Merck & Co Inc Combinations of protease inhibitors for the treatment of hiv infection and aids
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0987853A1 (en) 1998-09-17 2000-03-22 STMicroelectronics S.r.l. A fully digital phase aligner
TWI408264B (en) 2005-12-15 2013-09-11 Saint Gobain Cristaux & Detecteurs New process for growth of low dislocation density gan
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap

Also Published As

Publication number Publication date
EP1210941A3 (en) 2002-07-31
JP2012111775A (en) 2012-06-14
DK0871465T3 (en) 2003-02-03
EP2295052A1 (en) 2011-03-16
IL122546A (en) 2012-01-31
ATE392895T1 (en) 2008-05-15
ES2441736T3 (en) 2014-02-06
EP1284140A2 (en) 2003-02-19
DK2295052T3 (en) 2014-01-20
DE69637511D1 (en) 2008-06-05
PT871465E (en) 2003-02-28
US20020039998A1 (en) 2002-04-04
JP4023823B2 (en) 2007-12-19
PT2295052E (en) 2014-01-23
JPH11508884A (en) 1999-08-03
DE69637976D1 (en) 2009-09-03
EP2295052B1 (en) 2014-01-08
DE69624136D1 (en) 2002-11-07
JP2015013878A (en) 2015-01-22
PT1293207E (en) 2009-08-11
WO1997001349A1 (en) 1997-01-16
EP2130534A1 (en) 2009-12-09
JP5364871B2 (en) 2013-12-11
EP0871465A1 (en) 1998-10-21
ES2304416T3 (en) 2008-10-16
AU6342096A (en) 1997-01-30
EP1293207A1 (en) 2003-03-19
MX9710403A (en) 1998-07-31
EP1273298A2 (en) 2003-01-08
DK1284140T3 (en) 2008-08-18
EP0871465B1 (en) 2002-10-02
ES2328559T3 (en) 2009-11-16
IL122546A0 (en) 1998-06-15
US6037157A (en) 2000-03-14
HK1053783A1 (en) 2003-11-07
ATE225186T1 (en) 2002-10-15
KR19990028407A (en) 1999-04-15
EP1210941A2 (en) 2002-06-05
AU722812B2 (en) 2000-08-10
JP2007291131A (en) 2007-11-08
DE69637511T2 (en) 2009-06-04
HK1049103A1 (en) 2003-05-02
DK1293207T3 (en) 2009-10-05
ES2186787T3 (en) 2003-05-16
KR20070120619A (en) 2007-12-24
CA2224738A1 (en) 1997-01-16
EP1284140B1 (en) 2008-04-23
HK1053782A1 (en) 2003-11-07
EP1293207B1 (en) 2009-07-22
US6703403B2 (en) 2004-03-09
DE69624136T2 (en) 2003-08-14
HK1016088A1 (en) 1999-10-29
PT1284140E (en) 2008-05-14
EP1284140A3 (en) 2003-03-19
EP1273298A3 (en) 2003-03-19
KR100824547B1 (en) 2008-11-04

Similar Documents

Publication Publication Date Title
CA2224738C (en) Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids
KR100516567B1 (en) Pharmaceutical composition comprising an HIV protease inhibiting compound
US5578597A (en) Combination therapy for HIV infection
JPH10507202A (en) Pharmaceutical composition comprising proteinase inhibitor and monoglyceride
EP0691345A2 (en) HIV protease inhibitor combinations
US6180634B1 (en) Combination therapy for the treatment of AIDS
AU759386B2 (en) Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
EP1044000B1 (en) Combination therapy for the treatment of aids
MXPA97010403A (en) Use of ritonavir (abt-538) to improve the pharmacokinetics of metabolised drugs through cytochrome p450 in a method for the treatment of the

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160628